kisplyx
eisai gmbh - lenvatinib-mesilaatti - karsinooma, munuaissolut - antineoplastiset aineet - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastiset aineet - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
fingolimod accord
accord healthcare s.l.u. - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit, selektiiviset immunosuppressantit - taudinkulkua muuntavana lääkityksenä erittäin aktiivisen relapsoivan-remittoivan multippeliskleroosin seuraavat ryhmät aikuisille potilaille ja lapsipotilaille vuotiaista 10 vuotta ja vanhemmat:potilaat, joilla on erittäin aktiivinen tauti huolimatta täydellinen ja asianmukainen hoito vähintään yhdellä taudin kulkuun therapyorpatients kanssa vaikea ja nopeasti etenevä relapsoiva-remittoiva multippeliskleroosi on määritelty 2 tai enemmän invaliditeettiin sairauden pahenemisvaiheita on yksi vuosi, ja 1 tai enemmän gadolinium parantaa vaurioita aivojen mri tai merkittävä kasvu t2-leesio kuormitus verrattuna aiempaan tuoreeseen magneettikuvaukseen.
fingolimod avansor 0.5 mg kapseli, kova
avansor pharma oy - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
calquence
astrazeneca ab - acalabrutinib - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
fingolimod ailon 0.5 mg kapseli, kova
ailon pharma oy - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod ratiopharm 0.25 mg kapseli, kova
ratiopharm gmbh - fingolimod hydrochloride - kapseli, kova - 0.25 mg - fingolimodi
fingolimod ratiopharm 0.5 mg kapseli, kova
ratiopharm gmbh - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod zentiva 0.5 mg kapseli, kova
zentiva, k.s. - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi
fingolimod orion 0.5 mg kapseli, kova
orion corporation - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi